medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2013, Number 2

<< Back

Residente 2013; 8 (2)

Modificaciones en los títulos de anticuerpos antipéptidos cíclicos citrulinados (ANTI-CCP) con el uso de agentes antifactor de necrosis tumoral alfa (ANTI-TNF) en pacientes con artritis reumatoide

Loaiza-Cárdenas C, Murillo-Vázquez JD, Pérez-Guerrero EE, Bonilla-Lara D, Aguilar-Chávez ÉA, González-López L

Language: Spanish
References: 53
Page: 70-80
PDF size: 284.36 Kb.


ABSTRACT

Anticyclic citrullinated peptide antibodies constitute auto-antibodies directed against to citrullinated proteins that are highly prevalent in rheumatoid arthritis. High titles of anticyclic citrullinated peptide antibodies in serum can be observed in early stages of erosive disease. Tumor necrosis factor-alpha plays a relevant role on the pathogenesis of inflammatory process in rheumatoid arthritis and constitutes a target for some therapies with the aim to obtain a significant control of the disease activity. To date, antitumor necrosis factor-alpha agents are one of the most effective strategies to achieve the appropriate control of disease activity in rheumatoid arthritis, although the clinical effect of these agents on the antibodies titles are not well identified. This non-systematic review evaluates the evidence observed in longitudinal studies about the effect of antitumor necrosis factor-alpha agents on the serum levels on anticyclic citrullinated peptide antibodies.


REFERENCES

  1. Gabriel SE, Crowson CS, O’Fallon M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis & Rheumatism. 1999; 42(3): 415-420.

  2. Bingham CO 3rd. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. The Journal of Rheumatology Supplement. 2002; 65: 3-9.

  3. Sánchez-Ramón S, López-Longo FJ, Carreño L. Interleucinas en la fisiopatología de la artritis reumatoide: más allá de las citocinas proinflamatorias. Reumatología Clínica. 2011; 6(Supp 3): 20-24.

  4. Sanchez-Ramon S, Lopez-Longo FJ, Carreno L. Interleukins network in rheumatoid arthritis pathophysiology: beyond proinflammatory cytokines. Reumatol Clin. 2011; 6(Supp3): S20-24.

  5. Hernández-Urzúa MA, Alvarado-Navarro A. Interleucinas e inmunidad innata. Rev Biomed. 2001; 12(4): 272-280.

  6. Pesce B, Soto L, Sabugo F, Wurmann P, Cuchacovich M, Lopez MN et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clinical and experimental immunology. 2013; 171(3): 237-242.

  7. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nature reviews Rheumatology. 2009; 5(10): 549-553.

  8. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmunity reviews. 2007; 7(1): 35-41.

  9. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Annals of the rheumatic diseases. 2005; 64(3): 403-437.

  10. American College of Rheumatology. Guidelines for the management of rheumatoid arthritis. Arthritis & Rheumatism. 1996; 39(5): 713-722.

  11. American College of Rheumatology, Subcommittee on Rheumatoid Arthritis G. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis & Rheumatism. 2002; 46(2): 328-346.

  12. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis research. 2002; 4(2): 87-93.

  13. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. The Journal of clinical investigation. 1995; 95(6): 2672-2679.

  14. Gan SQ, McBride OW, Idler WW, Markova N, Steinert PM. Organization, structure, and polymorphisms of the human profilaggrin gene. Biochemistry. 1990; 29(40): 9432-9440.

  15. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and rheumatism. 2000; 43(1): 155-163.

  16. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Annals of internal medicine. 2007; 146(11): 797-808.

  17. Lutteri L, Malaise M, Chapelle JP. Comparison of second-and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clinica Chimica Acta. 2007; 386: 76-81.

  18. Luis Caro-Oleas J, Fernandez-Suarez A, Reneses Cesteros S, Porrino C, Nunez-Roldan A, Wichmann Schlipf I. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clinical chemistry and laboratory medicine: CCLM/FESCC. 2007; 45(10): 1396-1401.

  19. Enriconi dos Anjos L, Pereira I, d‘Orsi E, Seaman A, Burlingame R, Morato E. A comparative study of IgG second-and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol. 2009; 28(2): 153-158.

  20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and rheumatism. 2010; 62(9): 2569-2581.

  21. Gabriel SE, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis and rheumatism. 1999; 42(3): 415-420.

  22. Atzeni F, Sarzi-Puttini P, Dell’ Acqua D, de Portu S, Cecchini G, Cruini C et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis research & therapy. 2006; 8(1): R3.

  23. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health technology assessment. 2006; 10(42): 1-229.

  24. Szekanecz Z, Szabo Z, Zeher M, Soos L, Danko K, Horvath I et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunologic research. 2013; 56(2-3): 439-443.

  25. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chales G, Le Henaff C et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. The Journal of rheumatology. 2003; 30(12): 2535-2539.

  26. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health technology assessment. 2011; 15(14): 1-278.

  27. Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatology international. 2005; 26(1): 58-62.

  28. Calabrese LH. Molecular differences in anticytokine therapies. Clinical and experimental rheumatology. 2003; 21(2): 241-248.

  29. Haraoui B, Bykerk V. Etanercept in the treatment of rheumatoid arthritis. Therapeutics and clinical risk management. 2007; 3(1): 99-105.

  30. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC medicine. 2013; 11: 88.

  31. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the rheumatic diseases. 2009; 68(6): 797-804.

  32. Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology. 2011; 50(2): 261-70.

  33. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. Journal of immunology. 2003; 171(4): 1684-1690.

  34. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis research & therapy. 2009; 11(3): 84.

  35. Fekete A, Soos L, Szekanecz Z, Szabo Z, Szodoray P, Barath S et al. Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. Journal of autoimmunity. 2007; 29(2): 154-163.

  36. Cuchacovich M, Catalan D, Wainstein E, Gatica H, Soto L, Aravena O et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titles are associated with clinical response to adalimumab in rheumatoid arthritis. Clinical and experimental rheumatology. 2008; 26(6): 1067-1073.

  37. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Annals of the rheumatic diseases. 2004; 63 (10): 1218-1221.

  38. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis research & therapy. 2004; 6(3): R264-272.

  39. De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005; 64(2): 299-302.

  40. Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. The Journal of Rheumatology. 2008; 35(10): 1972-1977.

  41. Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. The Journal of Rheumatology. 2006; 33(3): 497-500.

  42. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2006; 65(1): 35-39.

  43. Onishi S, Yoshio T, Nagashima T, Minota S. Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-alpha. Modern rheumatology/the Japan Rheumatism Association. 2010; 20(5): 528-530.

  44. Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint, bone, spine: revue du rhumatisme. 2009; 76(3): 248-253.

  45. Bacquet-Deschryver H, Jouen F, Quillard M, Menard JF, Goeb V, Lequerre T et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. Journal of Clinical Immunology. 2008; 28(5): 445-455.

  46. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Annals of the Rheumatic Diseases. 2003; 62(9): 870-874.

  47. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. The Netherlands journal of medicine. 2002; 60(10): 383-388.

  48. Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clinical Chemistry. 2007; 53(8): 1527-1533.

  49. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis and Rheumatism. 2004; 50(3): 709-715.

  50. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford, England). 2006; 45(4): 478-480.

  51. Swart A, Burlingame RW, Gürtler I, Mahler M. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clinica Chimica Acta. 2012; 414(0): 266-272.

  52. Shidara K, Inoue E, Tanaka E, Hoshi D, Seto Y, Nakajima A et al. Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis. Rheumatology international. 2011; 31(5): 617-622.

  53. Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A et al. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatology International. 2006; 26(3): 209-214.




2020     |     www.medigraphic.com